Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Hypertension, proteinuria, baseline renal function, and MEST-C score are known prognostic factors in IgA nephropathy. In Japan, the efficacy of tonsillectomy has also been reported. Using our renal biopsy database, we investigated the impact of treatment and pathological findings on renal prognosis in addition to these established factors.
Among 2,481 patients who underwent renal biopsy between March 2001 and May 2023, 356 were diagnosed with IgA nephropathy. After excluding 111 cases with missing data, 7 cases with exclusionary diseases, 45 repeat biopsies, and 16 patients younger than 18 years, 177 patients with newly diagnosed IgA nephropathy were included in the final analysis. Clinical characteristics, laboratory and pathological findings, and treatments within 6 months were evaluated. The primary endpoint was the time from biopsy to a 1.5-fold increase in serum creatinine. Continuous variables are expressed as mean ± standard error (SE). Survival analyses were performed using the Kaplan–Meier method with log-rank test and the Cox proportional hazards model. JMP Student Edition 18 was used for statistical analyses, and p<0.05 was considered statistically significant.
Baseline characteristics were as follows: mean age 41.5±1.1 years , 80 males (45%), BMI 22.9±0.3, history of hypertension in 78 patients (44%), and diabetes mellitus in 8 patients (4.5%). Mean eGFR was 69.0±23.3 mL/min/1.73 m². Urinary occult blood was positive in 155 patients (88%), mean urinary protein excretion was 1.07±0.11 g/day, IgA 319.2±8.1 mg/dL, IgG 1,103.4±20.8 mg/dL, IgM 93.9±3.6 mg/dL, C3 98.7±1.5 mg/dL, C4 23.9±0.6 mg/dL, and CH50 41.1±0.5 U/mL. Oxford classification was E1 in 93 cases (52.5%), S0 in 46 (26%), S1 in 131 (74%), T0 in 150 (87%), T1 in 18 (10%), T2 in 5 (3%), C0 in 55 (31%), C1 in 112 (64%), and C2 in 9 (5%). Treatments administered within 6 months after biopsy included RAS inhibitors in 105 patients (59%), prednisolone in 98 (55%), methylprednisolone pulse in 85 (48%), other immunosuppressants in 11 (6.2%), SGLT2 inhibitors in 4 (2.3%), and tonsillectomy in 79 (45%). The median follow-up was 1701 days (IQR 862.5–2754), during which 19 patients (11%) reached the primary endpoint. In univariate analysis, age, male sex, hypertension, eGFR, proteinuria, T score, and tonsillectomy were significantly associated with outcome. In multivariate analysis, independent prognostic factors were age (HR 1.05 [95% CI 1.01–1.09], p=0.0163), diabetes mellitus (HR 6.53 [95% CI 1.15–37.09], p=0.0341), eGFR (HR 0.96 [95% CI 0.92–0.99], p=0.0144), and proteinuria (HR 1.92 [95% CI 1.28–2.93], p=0.0019). Sex, hypertension, RAS inhibitors, T score, and tonsillectomy were not independent prognostic factors.
This study is characterized by the inclusion of newly diagnosed IgA nephropathy patients with active disease, of whom as many as 45% underwent tonsillectomy. Tonsillectomy was associated with improved renal prognosis in univariate analysis, but independent risk factors identified in multivariate analysis were older age, diabetes mellitus, higher proteinuria, and lower eGFR. Limitations include the small number of events, insufficient power, retrospective design, and possible residual confounding. Further studies are needed to determine optimal treatment strategies for IgA nephropathy.
